Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Amoxicillin/clavulanic acid extra strength - GSK

Next Previous
Drug Profile

Amoxicillin/clavulanic acid extra strength - GSK

Alternative Names: Augmentin (ES)-600; Augmentin ES; Augmentin ES Chewable; Augmentin ES-600; Augmentin Extra Strength - GSK; Dry syrup formulation of Augmentin ES; Extra strength amoxicillin/clavulanate potassium - GSK; Extra-strength amoxicillin/clavulanic acid

Latest Information Update: 11 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Developer GSK
  • Class 2 ring heterocyclic compounds; Antibacterials; Azetidines; Beta-lactams; Carboxylic acids; Oxazolidinones; Penicillins; Small molecules
  • Mechanism of Action Beta lactamase inhibitors; Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Otitis media
  • Discontinued Rhinosinusitis

Most Recent Events

  • 25 Mar 2025 GlaxoSmithKline withdraws a phase II trial for community acquired pneumonia (CAP) and acute bacterial rhinosinusitis (ABRS) (In Children) prior to enrolment in Brazil (NCT05340257)
  • 22 Apr 2022 GlaxoSmithKline plans a phase II trial for community acquired pneumonia (CAP) and acute bacterial rhinosinusitis (ABRS) (In Children) in Brazil in 2022 (NCT05340257)
  • 22 Dec 2020 Chemical structure information added

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top